4basebio PLC has announced a change at the top of its leadership team, with Dr Amy Walker, previously the company's chief operating officer, taking over as chief executive officer. The company confirmed the appointment on Tuesday, saying Dr Walker will replace Dr Heikki Lanckriet.
Dr Walker has been with 4basebio for more than five years and served as COO at a pivotal moment for the business - during the period when 4basebio secured regulatory approval for its manufacturing site. The company cited her operational experience in conjunction with that milestone when describing the leadership change.
The outgoing CEO, Dr Heikki Lanckriet, will remain involved with 4basebio as a member of the board. In a concurrent move, Dr Lanckriet will spin out the company's Hermes platform - a technology that enables DNA delivery into cells using nanoparticles rather than viral vectors - as the basis for a new therapeutics venture. The company said Hermes is expected to provide the foundation for a separately-funded therapeutics business, in which 4basebio will retain an equity stake.
Alongside the CEO transition, 4basebio confirmed additional executive changes that preceded this announcement. In September 2025, the company appointed Chrissy Wolosin to head its commercial function; Wolosin joined from roles at Thermo Fisher and TriLink, according to the company's statement. Earlier, in July 2025, Dr Manja Boerman came on board as Executive Chair, with prior experience at companies including Catalent and Patheon.
Finance chief David Roth will step down from his CFO role at the same time as Dr Lanckriet's transition, but 4basebio said Roth will continue to work with the company as a consultant to support a smooth handover while a search for a new chief financial officer is conducted.
Context and next steps
The company described the Hermes platform as the centerpiece of the planned therapeutics vehicle, which is intended to be funded separately from 4basebio's core operations. 4basebio will retain an equity stake in that new business. The firm also highlighted the recent commercial and governance hires from September 2025 and July 2025 as part of its broader executive reorganization.
Details on timing for the Hermes spin-out, the funding arrangements for the therapeutics business, and the timetable for appointing a new CFO were not specified in the company announcement.